Get startedLog in
    Picture of Atossa Therapeutics logo

    ATOS — Atossa Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousMicro CapNeutral
    All News

    Atossa Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview

    Picture of Atossa Therapeutics logoAtossa Therapeutics
    09/05/2025 16:12
    Atossa Therapeutics Inc ATOS.OQ ATOS.O is expected to show no change in quarterly revenue when it reports  results on May 12 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Atossa Therapeutics Inc is for a loss of 6 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Atossa Therapeutics Inc is $7.00​, above​ its last closing price of $0.81. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​


    QUARTER ENDINGSTARMINESMARTESTIMATE®LSEG IBES ESTIMATEACTUALBEAT, MET, MISSEDSURPRISE %
    Dec. 31 2024-0.06-0.05Beat21
    Sep. 30 2024-0.05-0.06-0.06Met-5.9
    Jun. 30 2024-0.06-0.06-0.05Beat11.8​
    Mar. 31 2024-0.07-0.07-0.05Beat25
    ​​Dec. 31 2023-0.05-0.06-0.09Missed-58.8
    Sep. 30 2023-0.07-0.07-0.05Beat28.6​
    Jun. 30 2023-0.06-0.08Missed-33.3
    Mar. 31 2023-0.06-0.05Beat16.7
    

This summary was machine generated May 9 at 15:12 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

    Recent news on Atossa Therapeutics

    See all news